Eli Lilly is on a hot streak. It’s about to find out whether its diabetes drug can also be marketed for weight management. Its Alzheimer’s disease therapy is also expected to get a decision from the FDA by the end of the year. And it’s been steadily inking deals — five acquisitions in as many months (with hints of a few that are still under wraps).
Endpoints News spoke with Lilly’s multi-hyphenated executive Dan Skovronsky about Lilly’s M&A plans, playing the long game in drug development and why it doesn’t need mega deals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.